4//SEC Filing
Danos Olivier 4
Accession 0001562180-24-000249
CIK 0001590877other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 4:22 PM ET
Size
13.7 KB
Accession
0001562180-24-000249
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
Danos Olivier
Chief Scientific Officer
Transactions
- Award
Stock Options (Right to buy)
2024-01-02+61,050→ 61,050 totalExercise: $18.34Exp: 2034-01-02→ Common Stock (61,050 underlying) - Award
Common Stock
2022-06-30$21.00/sh+728$15,284→ 93,678 total - Award
Common Stock
2023-06-30$16.99/sh+1,123$19,081→ 94,801 total - Tax Payment
Common Stock
2024-01-02$17.95/sh−8,410$150,960→ 86,391 total - Award
Common Stock
2024-01-02+38,462→ 124,853 total
Footnotes (7)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is exempt under Rule 16b-3(c).
- [F2]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022.
- [F3]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2023 through June 30, 2023. This transaction is exempt under Rule 16b-3(c).
- [F4]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2023.
- [F5]Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the Issuer's common stock on December 29, 2023.
- [F6]Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer.
- [F7]25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer.
Documents
Issuer
REGENXBIO Inc.
CIK 0001590877
Entity typeother
Related Parties
1- filerCIK 0001701180
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 4:22 PM ET
- Size
- 13.7 KB